HC Wainwright Predicts Lower Earnings for Oncolytics Biotech

Oncolytics Biotech Inc. (TSE:ONC) – Equities research analysts at HC Wainwright decreased their Q3 2025 EPS estimates for Oncolytics Biotech in a research note issued on Tuesday, September 16th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.16) for the quarter, down from their prior estimate of ($0.15). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2025 earnings at ($0.39) EPS.

Separately, Lake Street Capital upgraded shares of Oncolytics Biotech to a “strong-buy” rating in a report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of C$3.50.

Oncolytics Biotech Stock Down 1.3%

ONC opened at C$14.90 on Thursday. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The company’s 50-day moving average is C$6.33 and its 200 day moving average is C$2.72. Oncolytics Biotech has a fifty-two week low of C$0.44 and a fifty-two week high of C$2.08. The firm has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80.

Insider Transactions at Oncolytics Biotech

In other news, Senior Officer Thomas Heineman bought 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 17th. The shares were bought at an average cost of C$1.74 per share, with a total value of C$26,098.50. Also, Senior Officer Jared Ryan Kelly acquired 50,400 shares of Oncolytics Biotech stock in a transaction on Wednesday, July 16th. The shares were bought at an average cost of C$1.63 per share, for a total transaction of C$82,284.50. In the last ninety days, insiders acquired 108,300 shares of company stock worth $178,192. 3.82% of the stock is currently owned by insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.